Taysha reports Q2 net loss $20.9M, cash $172.7M; TSHA-102 high dose data in 1H 2025

Taysha Gene Therapies, Inc.

2024-Q2 EPS reported -$0.19 revenue$4,523,000

Net loss narrowed to $20.9M ($0.09/share) from $24.6M ($0.38/share) in Q2 2023.
Cash $172.7M at June 30; runway extended into Q4 2026 after $76.8M public offering.
TSHA-102 low dose data showed durable improvements and no SAEs/DLTs in adult and pediatric trials.
High dose cohort dosing started; safety/efficacy data from both REVEAL trials expected 1H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.